Research suggests that lower doses of treatment may be effective in treating melanoma, with some studies indicating better results from low-dose immunotherapy for skin cancer. However, the effectiveness of certain treatments, such as fianlimab, is unclear, with one study finding no significant improvement in progression-free survival. Other approaches, including novel immunotherapy delivery methods and tumor-infiltrating lymphocyte therapy, are also being explored for their potential in treating melanoma.